Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1158/0008-5472.CAN-15-0694PMID 26677977PMCID PMC4713045
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.

  2015cited by this paper
• The UCSC Cancer Genomics Browser: update 2015

  2014cited by this paper
• Association of Toxicity of Sorafenib and Sunitinib for Human Keratinocytes with Inhibition of Signal Transduction and Activator of Transcription 3 (STAT3)

  2014cited by this paper
• Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

  2013cited by this paper
• Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia

  2013cited by this paper
• Integrating Clinical Pharmacology Concepts in Individualized Therapy With Tyrosine Kinase Inhibitors

  2013cited by this paper
• TAK1 regulates SCF expression to modulate PKBα activity that protects keratinocytes from ROS-induced apoptosis

  2011cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.

  2011cited by this paper
• In situ kinase profiling reveals functionally relevant properties of native kinases.

  2011cited by this paper
• Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

  2011cited by this paper
• Comprehensive analysis of kinase inhibitor selectivity

  2011cited by this paper
• Lack of Association Between Excretion of Sorafenib in Sweat and Hand‐Foot Skin Reaction

  2010cited by this paper
• Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).

  2009cited by this paper
• Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

  2009cited by this paper
• Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology.

  2009cited by this paper
• Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

  2009cited by this paper
• Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

  2008cited by this paper
• TAK1 Regulates Reactive Oxygen Species and Cell Death in Keratinocytes, Which Is Essential for Skin Integrity*

  2008cited by this paper
• Functional interrogation of the kinome using nucleotide acyl phosphates.

  2007cited by this paper
• Transforming Growth Factor-β-activated Kinase 1 Is Essential for Differentiation and the Prevention of Apoptosis in Epidermis*

  2006cited by this paper
• Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.

  2006cited by this paper
• Epithelial stem cells: a folliculocentric view.

  2006cited by this paper
• Transport of estrone sulfate by the novel organic anion transporter Oat6 (Slc22a20).

  2006cited by this paper
• TAK1 Is a Master Regulator of Epidermal Homeostasis Involving Skin Inflammation and Apoptosis*

  2006cited by this paper
• Molecular biology of hair morphogenesis: development and cycling.

  2003cited by this paper
• Discovery of a novel Raf kinase inhibitor.

  2001cited by this paper
• A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages.

  2001cited by this paper
• Characterization of a novel human putative mitochondrial transporter homologous to the yeast mitochondrial RNA splicing proteins 3 and 4

  2001cited by this paper
• The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway

  1999cited by this paper

• Role of solute carrier transporters in the biodistribution and toxicity of chemotherapeutic drugs.

  2026cites this paper
• Cyclin-dependent kinase inhibitor abemaciclib-induced cutaneous responses mediated by inflammation.

  2025cites this paper
• Sorafenib‐Related Dermatologic Toxicity: A Comprehensive Evaluation Based on Disproportionality Analysis and Clinical Characteristics

  2025cites this paper
• Dual inhibition of IRAK1/TAK1 signaling in astrocytes reduces accelerated mortality in human APOE4 knock-in APPswe/PSEN1dE9/P301S-Tau triple transgenic mouse model

  2025cites this paper
• Targeting TAK1: Evolution of inhibitors, challenges, and future directions.

  2025cites this paper
• Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma

  2024cites this paper
• AR loss in prostate cancer stroma mediated by NF-κB and p38-MAPK signaling disrupts stromal morphogen production

  2024cites this paper
• Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis

  2023cites this paper
• Evaluation of Delayed-Type Hypersensitivity to Antineoplastic Drugs—An Overview

  2023cites this paper
• Nitric Oxide in Multikinase Inhibitor-induced Hand-Foot Skin Reaction.

  2022cites this paper
• Evaluation of Antineoplastic Delayed-Type Hypersensitivity Skin Reactions In Vitro

  2022cites this paper
• Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition.

  2022cites this paper
• TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance

  2021cites this paper
• Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer

  2021cites this paper
• Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib

  2020cites this paper
• Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration

  2020cites this paper
• Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients.

  2020cites this paper
• Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.

  2020cites this paper
• Clinical study for external Chinese herbal medicine LC09 treating hand-foot skin reaction associated with the antitumor targeted drugs

  2020cites this paper
• Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis.

  2020cites this paper
• Solute transporters and malignancy: establishing the role of uptake transporters in breast cancer and breast cancer metastasis

  2020cites this paper
• MTDH Inhibits K48-Linked Degradation of TAK1 and Promotes Sorafenib Resistance in Hepatocellular Carcinoma

  2020cites this paper
• Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management

  2019cites this paper
• Clinically relevant drug interactions with multikinase inhibitors: a review

  2019cites this paper
• Influx and Efflux Transporters Contribute to the Increased Dermal Exposure to Active Metabolite of Regorafenib After Repeated Oral Administration in Mice.

  2019cites this paper
• Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.

  2019cites this paper
• Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies

  2019cites this paper
• Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies

  2018cites this paper
• Juglone–ascorbic acid synergy inhibits metastasis and induces apoptotic cell death in poorly differentiated thyroid carcinoma by perturbing SOD and catalase activities

  2018cites this paper
• MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB

  2018cites this paper
• Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies

  2018cites this paper
• SCARs induced by targeted therapies and immunotherapies Search strategy and selection criteria

  2018cites this paper
• Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition

  2018cites this paper
• Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites.

  2017cites this paper
• Identification of novel risk variants for sarcoma and other cancers by whole exome sequencing analysis in cancer cluster families

  2017cites this paper
• Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease

  2017cites this paper
• Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation

  2017cites this paper
• Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia

  2017cites this paper
• Sorafenib stimulates human skin type mast cell degranulation and maturation.

  2017cites this paper
• Cutaneous Toxicities of Molecular Targeted Therapies.

  2017cites this paper
• Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition☆

  2017cites this paper
• Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology.

  2017cites this paper
• Loss of SLCO1B3 drives taxane resistance in prostate cancer

  2016cites this paper
• Multikinase Inhibitor-Induced Hand–Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management

  2016cites this paper
• Systematic Analysis of Quantitative Logic Model Ensembles Predicts Drug Combination Effects on Cell Signaling Networks

  2016cites this paper
• Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors.

  2016cites this paper
• Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib

  2016cites this paper